PURE Bioscience to Present at the 9th Annual LD Micro Conference

SAN DIEGO, CA / ACCESSWIRE / November 21, 2016 / PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Hank R. Lambert, CEO, will present at the 9th Annual LD Micro Conference on Tuesday, December 6th at 11:00am PST, at the Luxe Hotel Sunset Boulevard in Los Angeles. The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting names.

Lambert will discuss the Company's dual path strategy to establish PURE's patented SDC antimicrobial technology as a novel and proprietary food safety solution, effective against pathogens including Salmonella, E. coli, Listeria and Norovirus:

• EPA registered PURE® Hard Surface disinfectant
• Ongoing sales to Chipotle Mexican Grill and other restaurants and expanding use with + 40 national food processors; presently +$2 million annualized run rate
• FDA approved PURE Control® direct food contact processing aid
• Sales & marketing to fresh produce processors
• Progress on pending final USDA approval for raw poultry processing
• Est. combined +$650 million US market opportunity

The presentation will be webcast live and slides may be accessed on the Company's website, http://www.purebio.com/investors/events-presentations/. The presentation will be archived for 90 days.

View PURE Bioscience's profile here: http://www.ldmicro.com/profile/PURE

News Compliments of Accesswire

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.

About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena - providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company's ability to convert successful evaluations and tests into customer orders and customers continuing to place product orders as expected and to expand their use of the Company's products; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2016, its Form 10-Q for the first quarter ended October 31, 2015 and its Form 10-Q for the second quarter ended January 31, 2016, and its Form 10-Q for the third quarter ended April 30, 2016. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contacts:
Hank Lambert, CEO
PURE Bioscience, Inc.
619-596-8600 ext.103
hlambert@purebio.com

Terri MacInnis, VP of IR
Bibicoff + MacInnis, Inc.
818-379-8500
terri@bibimac.com

Tom Hemingway
Redwood Investment Group
714-978-4425
tomh@redwoodfin.com

SOURCE: PURE Bioscience, Inc.